AIM
VRTX icon

Anchor Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Anchor Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131K Sell
263
-128
-33% -$56.7K 0.01% 443
2026
Q1 		$175K Sell
391
-104
-21% -$48.5K 0.01% 403
2025
Q4 		$224K Sell
495
-1,892
-79% -$816K 0.02% 361
2025
Q3 		$935K Buy
2,387
+770
+48% +$322K 0.08% 198
2025
Q2 		$720K Buy
1,617
+2
+0.1% +$922 0.06% 219
2025
Q1 		$783K Buy
1,615
+209
+15% +$97.4K 0.07% 206
2024
Q4 		$566K Sell
1,406
-177
-11% -$82K 0.05% 236
2024
Q3 		$736K Buy
1,583
+1,474
+1,352% +$708K 0.07% 219
2024
Q2 		$51.1K Sell
109
-2,032
-95% -$882K 0.01% 514
2024
Q1 		$895K Buy
2,141
+168
+9% +$71K 0.09% 190
2023
Q4 		$803K Buy
1,973
+297
+18% +$110K 0.09% 188
2023
Q3 		$583K Buy
1,676
+378
+29% +$132K 0.08% 213
2023
Q2 		$457K Buy
1,298
+633
+95% +$213K 0.06% 240
2023
Q1 		$210K Buy
665
+41
+7% +$12.3K 0.03% 337
2022
Q4 		$180K Buy
624
+614
+6,140% +$187K 0.03% 351
2022
Q3 		$2.9K Hold
10
– – ﹤0.01% 863
2022
Q2 		$2.82K Hold
10
– – ﹤0.01% 867
2022
Q1 		$2.61K Hold
10
– – ﹤0.01% 894
2021
Q4 		$2.2K Hold
10
– – ﹤0.01% 930
2021
Q3 		$1.81K Hold
10
– – ﹤0.01% 864
2021
Q2 		$2.02K Sell
10
-675
-99% -$141K ﹤0.01% 879
2021
Q1 		$147K Buy
685
+525
+328% +$115K 0.02% 384
2020
Q4 		$37.8K Buy
160
+115
+256% +$26.4K 0.01% 511
2020
Q3 		$12.2K Buy
45
+35
+350% +$9.66K ﹤0.01% 626
2020
Q2 		$2.9K Buy
+10
New +$2.71K ﹤0.01% 754

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Anchor Investment Management's VRTX Position: Q2 2026 in Review

Anchor Investment Management reduced its Vertex Pharmaceuticals (VRTX) stake by 33% in Q2 2026, selling an estimated $56.7K and leaving 263 shares worth $131K. The position accounts for 0.01% of the portfolio, ranked #443.

Anchor Investment Management first reported a position in VRTX in Q2 2020 and has held it in 25 quarters since. The position peaked at $935K in Q3 2025. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Anchor Investment Management held 263 shares of Vertex Pharmaceuticals worth $131K as of Q2 2026.
  • Anchor Investment Management sold 128 Vertex Pharmaceuticals shares in Q2 2026, an estimated $56.7K.
  • Vertex Pharmaceuticals made up 0.01% of Anchor Investment Management's portfolio in Q2 2026, its #443 holding.
  • Anchor Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Anchor Investment Management's Vertex Pharmaceuticals position peaked at $935K in Q3 2025.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Anchor Investment Management's 13F filing for Q2 2026, filed 15 Sep 2026.